PD-1 antibody in combination with chemotherapy for the treatment of SMARCA4-deficient advanced undifferentiated carcinoma of the duodenum: Two case reports

Figure 2 Major response to immunochemotherapy and disease regression in case 2. A and B: A mass in the descending part of the duodenum and multiple retroperitoneal lymph node metastases initially observed; C and D: Significant disease regression after the administration of immunochemotherapy; E: H&E: The undifferentiated tumor cells were diffusely distributed, and patchy necrosis was observed; F: The SMARCA4 protein was negative for BRG1 according to immunohistology.